Two new studies highlight the potential of psilocybin, the active compound in psychedelic mushrooms, to improve mental health outcomes when combined with psychotherapy.
These findings build on growing evidence that carefully supervised psilocybin therapy can be both safe and effective for addressing psychological distress in various populations, including cancer patients and individuals struggling with alcohol use disorder.
The first study, published in Nature Mental Health, explored psilocybin’s effects on cancer patients dealing with anxiety, depression, and psychological distress.
Conducted by a team at NYU Langone Health, the research showed that one or two doses of psilocybin, accompanied by psychotherapy, significantly reduced symptoms such as obsessive thoughts, anger, and physical distress.
The improvements lasted up to six months after treatment. Importantly, participants did not report any lingering negative effects like paranoia or deep fear, which are sometimes associated with psychedelic experiences.
These results suggest that psilocybin therapy, under medical supervision, could offer a powerful tool for improving quality of life for cancer patients.
This study analyzed data from two earlier clinical trials involving 79 participants. In these trials, participants were randomly assigned to receive either a high dose of psilocybin or a placebo, such as vitamin B3 or a very small dose of psilocybin. After several weeks, the groups switched treatments.
Psychotherapy was provided before and after each dosing session, and participants reported their mental health symptoms at the beginning of the study and six months after completing treatment. Across the board, those who received psilocybin showed significant improvements in mental health compared to those receiving the placebo.
The second study, published in a special edition of the American Journal of Psychiatry, focused on psilocybin’s impact on individuals with alcohol use disorder. Led by researchers from the same institution, this study found that psilocybin therapy not only reduced impulsivity and depression but also fostered lasting positive personality changes.
Participants became more open, accepting of their emotions, and resilient to stressors that often lead to relapse. These effects were still evident seven months after the second dose of psilocybin.
Interestingly, the study noted some gender-based differences: men experienced a boost in positive emotions, while women showed greater increases in openness. While the reasons for these differences remain unclear, the findings underscore psilocybin’s potential to support recovery by promoting healthier coping mechanisms and reducing behaviors linked to relapse.
Psilocybin works by influencing brain activity, often inducing profound changes in perception, emotions, and self-awareness. Many participants describe these experiences as personally or spiritually meaningful.
However, the drug is not without risks—it can raise blood pressure, increase heart rate, and cause overwhelming psychological effects. For this reason, researchers emphasize that psilocybin should only be used in controlled settings with thorough medical and psychological support.
While these studies demonstrate psilocybin’s promise, there are some limitations. Many participants guessed whether they had received psilocybin or a placebo, which could have influenced the results.
Moreover, further research is needed to understand how psilocybin might affect other disorders, such as opioid addiction, and to explore the gender-based differences observed in the second study.
These findings highlight the potential of psilocybin as a therapeutic tool when used responsibly and under professional supervision.
As research advances, it could pave the way for new treatments that address complex mental health and addiction challenges, offering hope to those who may not respond to traditional methods.
For more information about ADHD, please see recent studies about Nutrition’s role in managing ADHD: what you need to know and results showing that Food additives and ADHD: what parents should know.
If you care about ADHD, please read studies about 5 signs you have ADHD, not laziness, and new drug to reduce daydreaming, fatigue, and brain sluggishness in ADHD.
The research findings can be found in Nature Mental Health.
Copyright © 2025 Knowridge Science Report. All rights reserved.
